Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Sells $321,256.94 in Stock

Lifecore Biomedical, Inc. (NASDAQ:LFCR) major shareholder Aron R. English sold 45,698 shares of Lifecore Biomedical stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $7.03, for a total transaction of $321,256.94. Following the completion of the transaction, the insider now directly owns 1,662,574 shares of the company’s stock, valued at $11,687,895.22. This trade represents a 2.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Lifecore Biomedical Stock Down 0.4%

Shares of Lifecore Biomedical stock opened at $6.95 on Wednesday. The stock has a market capitalization of $257.32 million, a price-to-earnings ratio of -12.41 and a beta of 0.65. The business’s 50 day simple moving average is $6.45 and its 200-day simple moving average is $6.52. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21. Lifecore Biomedical, Inc. has a twelve month low of $3.68 and a twelve month high of $7.99.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. The firm had revenue of $35.15 million during the quarter, compared to analyst estimates of $33.23 million. Equities research analysts forecast that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current year.

Hedge Funds Weigh In On Lifecore Biomedical

Several large investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its position in shares of Lifecore Biomedical by 1,839.7% during the 1st quarter. GAMMA Investing LLC now owns 3,569 shares of the company’s stock valued at $25,000 after purchasing an additional 3,385 shares during the period. Summit Securities Group LLC purchased a new stake in shares of Lifecore Biomedical in the first quarter valued at $26,000. Hurley Capital LLC acquired a new stake in Lifecore Biomedical during the 1st quarter worth about $35,000. ARS Investment Partners LLC purchased a new position in Lifecore Biomedical during the fourth quarter valued at approximately $74,000. Finally, Prudential Financial Inc. acquired a new position in shares of Lifecore Biomedical in the fourth quarter worth $95,000. Institutional investors and hedge funds own 83.36% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.